SPROSpero Therapeutics Inc
$2.05
$0.05
(2.38%)
EarningsAug 11
Mkt Cap$121.59M
Vol880,470.00
Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz
The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.
24-7 Market News
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Zacks
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...
Business Wire
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...
Business Wire
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...
MarketBeat
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
Zacks
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average - What's Next?
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 50-Day Moving Average - Here's What Happened...
MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above Fifty Day Moving Average - Should You Sell...
MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Upgraded by Wall Street Zen to "Strong-Buy" Rating
Wall Street Zen raised shares of Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Estimates By $0.73 EPS
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts...
MarketBeat
<
1
2
...
>